Skin cancer: Targeted therapy for melanoma: Is double hitting a home run?

Nature Reviews Clinical Oncology

Volumn 10, Issue 1, 2013, Pages 5-6

  Smalley, Keiran S M ^a   Sondak, Vernon K ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE INHIBITOR; DABRAFENIB; TRAMETINIB; VEMURAFENIB; ANTINEOPLASTIC AGENT; B RAF KINASE; BRAF PROTEIN, HUMAN; MAP2K1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1;

CANCER COMBINATION CHEMOTHERAPY; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; HUMAN; MELANOMA; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NOTE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RISK ASSESSMENT; SKIN CARCINOMA; TREATMENT OUTCOME; ARTICLE; DRUG ANTAGONISM; DRUG EFFECT; PHASE 2 CLINICAL TRIAL (TOPIC); PROGNOSIS; SECOND CANCER; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; MAP KINASE KINASE 1; MELANOMA; MOLECULAR TARGETED THERAPY; NEOPLASMS, SECOND PRIMARY; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; SIGNAL TRANSDUCTION;

EID: 84871611623     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2012.215     Document Type: Note

References (10)

1. Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-316 (2011).
2. Hauschild, A. et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380, 358-365 (2012).
3. Su, F. et al. RAS Mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N. Engl. J. Med. 366, 207-215 (2012).
4. Paraiso, K. H. et al. Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br. J. Cancer 102, 1724-1730 (2010).
5. Flaherty, K. T. et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med. 367, 107-114 (2012).
6. Flaherty, K. T. et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367, 1694-1703 (2012).
7. Chapman, P. B. et al. Development of colonic adenomas and gastric polyps in BRAF mutant melanoma patients treated with vemurafenib [abstract]. Pigment Cell Melanoma Res. 25, 847 (2012).
8. Callahan, M. et al. Progression of RAS-mutant leukemia during RAF inhibitor treatment. N. Engl. J. Med. doi:10.1056/NEJMoa1208958.
9. Andrews, M. et al. Colorectal cancer promoted in a melanoma patient receiving dabrafenib (GSK2118436) in combination with MEK1/2 inhibitor trametinib (GSK1120212) [abstract]. Pigment Cell Melanoma Res. 25, 842 (2012).
10. Margolin, K. A. et al. Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438). Clin. Cancer Res. 18, 1129-1137 (2012).